Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

Hombach AA, Rappl G, Abken H.

Mol Ther. 2019 Oct 2;27(10):1825-1835. doi: 10.1016/j.ymthe.2019.06.007. Epub 2019 Jun 19.

PMID:
31331813
2.

Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform.

Aleksandrova K, Leise J, Priesner C, Melk A, Kubaink F, Abken H, Hombach A, Aktas M, Essl M, Bürger I, Kaiser A, Rauser G, Jurk M, Goudeva L, Glienke W, Arseniev L, Esser R, Köhl U.

Transfus Med Hemother. 2019 Feb;46(1):47-54. doi: 10.1159/000495772. Epub 2019 Feb 4. Review.

3.

CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.

Golumba-Nagy V, Kuehle J, Hombach AA, Abken H.

Mol Ther. 2018 Sep 5;26(9):2218-2230. doi: 10.1016/j.ymthe.2018.07.005. Epub 2018 Jul 10.

4.

CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.

Martyniszyn A, Krahl AC, André MC, Hombach AA, Abken H.

Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.

PMID:
29207878
5.
6.

Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?

Hombach AA, Abken H.

Expert Rev Clin Immunol. 2017 Feb;13(2):151-155. doi: 10.1080/1744666X.2016.1221763. Epub 2016 Aug 22. Review.

PMID:
27546707
7.

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.

Faitschuk E, Hombach AA, Frenzel LP, Wendtner CM, Abken H.

Blood. 2016 Sep 29;128(13):1711-22. doi: 10.1182/blood-2016-01-692046. Epub 2016 Aug 17.

PMID:
27535994
8.

A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv.

Faitschuk E, Nagy V, Hombach AA, Abken H.

Gene Ther. 2016 Oct;23(10):718-726. doi: 10.1038/gt.2016.48. Epub 2016 Jun 14.

PMID:
27356950
9.

Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Hombach AA, Görgens A, Chmielewski M, Murke F, Kimpel J, Giebel B, Abken H.

Mol Ther. 2016 Aug;24(8):1423-34. doi: 10.1038/mt.2016.82. Epub 2016 Apr 26.

10.

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.

Krug C, Birkholz K, Paulus A, Schwenkert M, Schmidt P, Hoffmann N, Hombach A, Fey G, Abken H, Schuler G, Schuler-Thurner B, Dörrie J, Schaft N.

Cancer Immunol Immunother. 2015 Dec;64(12):1623-35. doi: 10.1007/s00262-015-1767-4. Epub 2015 Oct 29.

PMID:
26515978
11.

Leishmania donovani P23 protects parasites against HSP90 inhibitor-mediated growth arrest.

Hombach A, Ommen G, Sattler V, Clos J.

Cell Stress Chaperones. 2015 Jul;20(4):673-85. doi: 10.1007/s12192-015-0595-y. Epub 2015 May 7.

12.

A small heat shock protein is essential for thermotolerance and intracellular survival of Leishmania donovani.

Hombach A, Ommen G, MacDonald A, Clos J.

J Cell Sci. 2014 Nov 1;127(Pt 21):4762-73. doi: 10.1242/jcs.157297. Epub 2014 Sep 1.

13.

Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.

Theissen J, Oberthuer A, Hombach A, Volland R, Hertwig F, Fischer M, Spitz R, Zapatka M, Brors B, Ortmann M, Simon T, Hero B, Berthold F.

Genes Chromosomes Cancer. 2014 Aug;53(8):639-49. doi: 10.1002/gcc.22174. Epub 2014 Apr 15.

PMID:
24737690
14.

No stress--Hsp90 and signal transduction in Leishmania.

Hombach A, Clos J.

Parasitology. 2014 Aug;141(9):1156-66. doi: 10.1017/S0031182013002151. Epub 2014 Apr 4.

PMID:
24703183
15.

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.

Chmielewski M, Hombach AA, Abken H.

Immunol Rev. 2014 Jan;257(1):83-90. doi: 10.1111/imr.12125. Review.

PMID:
24329791
16.

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells.

Chmielewski M, Hombach AA, Abken H.

Front Immunol. 2013 Nov 11;4:371. doi: 10.3389/fimmu.2013.00371. eCollection 2013. Review.

17.

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Hombach AA, Rappl G, Abken H.

Mol Ther. 2013 Dec;21(12):2268-77. doi: 10.1038/mt.2013.192. Epub 2013 Aug 28.

18.

Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.

Hombach AA, Abken H.

Immunotherapy. 2013 Jul;5(7):677-81. doi: 10.2217/imt.13.54. No abstract available.

PMID:
23829616
19.

Targeting two co-operating cytokines efficiently shapes immune responses.

Hombach AA, Abken H.

Oncoimmunology. 2013 Mar 1;2(3):e23205.

20.

Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle.

Hombach AA, Abken H.

Front Immunol. 2013 Jun 5;4:135. doi: 10.3389/fimmu.2013.00135. eCollection 2013.

21.

Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing.

Brinkmann K, Hombach A, Seeger JM, Wagner-Stippich D, Klubertz D, Krönke M, Abken H, Kashkar H.

Leuk Lymphoma. 2014 Mar;55(3):645-51. doi: 10.3109/10428194.2013.807925. Epub 2013 Jun 26.

PMID:
23697877
22.

Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.

Simon-Keller K, Paschen A, Hombach AA, Ströbel P, Coindre JM, Eichmüller SB, Vincent A, Gattenlöhner S, Hoppe F, Leuschner I, Stegmaier S, Koscielniak E, Leverkus M, Altieri DC, Abken H, Marx A.

Am J Pathol. 2013 Jun;182(6):2121-31. doi: 10.1016/j.ajpath.2013.02.017. Epub 2013 Apr 2.

23.

Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.

Hombach AA, Chmielewski M, Rappl G, Abken H.

Hum Gene Ther. 2013 Mar;24(3):259-69. doi: 10.1089/hum.2012.247.

PMID:
23350854
24.

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

Hombach AA, Holzinger A, Abken H.

Curr Mol Med. 2013 Aug;13(7):1079-88. Review.

PMID:
23116267
25.

The Hsp90-Sti1 interaction is critical for Leishmania donovani proliferation in both life cycle stages.

Hombach A, Ommen G, Chrobak M, Clos J.

Cell Microbiol. 2013 Apr;15(4):585-600. doi: 10.1111/cmi.12057. Epub 2012 Nov 20.

26.

An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.

Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, Abken H, Hombach AA.

PLoS One. 2012;7(9):e44482. doi: 10.1371/journal.pone.0044482. Epub 2012 Sep 18.

27.

Chimeric antigen receptors for T-cell based therapy.

Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, Gilham DE.

Methods Mol Biol. 2012;907:645-66. doi: 10.1007/978-1-61779-974-7_36.

PMID:
22907378
28.

Antibody-IL2 fusion proteins for tumor targeting.

Hombach AA, Abken H.

Methods Mol Biol. 2012;907:611-26. doi: 10.1007/978-1-61779-974-7_34.

PMID:
22907376
29.

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.

Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H.

Oncoimmunology. 2012 Jul 1;1(4):458-466.

30.

T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice.

Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA, Abken H.

Gastroenterology. 2012 Oct;143(4):1095-107.e2. doi: 10.1053/j.gastro.2012.06.037. Epub 2012 Jun 27.

PMID:
22750462
31.

A proteomic view at T cell costimulation.

Lichtenfels R, Rappl G, Hombach AA, Recktenwald CV, Dressler SP, Abken H, Seliger B.

PLoS One. 2012;7(4):e32994. doi: 10.1371/journal.pone.0032994. Epub 2012 Apr 23.

32.

Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells.

Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG.

Clin Dev Immunol. 2012;2012:238924. doi: 10.1155/2012/238924. Epub 2012 Mar 19.

33.

Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death.

Schmidt J, Barthel K, Zschüntzsch J, Muth IE, Swindle EJ, Hombach A, Sehmisch S, Wrede A, Lühder F, Gold R, Dalakas MC.

Brain. 2012 Apr;135(Pt 4):1102-14. doi: 10.1093/brain/aws046. Epub 2012 Mar 21.

PMID:
22436237
34.

T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term.

Chmielewski M, Rappl G, Hombach AA, Abken H.

Gene Ther. 2013 Feb;20(2):177-86. doi: 10.1038/gt.2012.21. Epub 2012 Mar 1.

PMID:
22378346
35.

The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells.

Rappl G, Riet T, Awerkiew S, Schmidt A, Hombach AA, Pfister H, Abken H.

PLoS One. 2012;7(1):e30713. doi: 10.1371/journal.pone.0030713. Epub 2012 Jan 23.

36.

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.

Hombach AA, Abken H.

Int J Cancer. 2011 Dec 15;129(12):2935-44. doi: 10.1002/ijc.25960. Epub 2011 Mar 29.

37.

Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.

Koehler P, Schmidt P, Hombach AA, Hallek M, Abken H.

Adv Hematol. 2012;2012:595060. doi: 10.1155/2012/595060. Epub 2011 Aug 8.

38.

IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.

Chmielewski M, Kopecky C, Hombach AA, Abken H.

Cancer Res. 2011 Sep 1;71(17):5697-706. doi: 10.1158/0008-5472.CAN-11-0103. Epub 2011 Jul 8.

39.

Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation.

Rappl G, Pabst S, Riemann D, Schmidt A, Wickenhauser C, Schütte W, Hombach AA, Seliger B, Grohé C, Abken H.

Clin Immunol. 2011 Jul;140(1):71-83. doi: 10.1016/j.clim.2011.03.015. Epub 2011 Mar 24.

PMID:
21482483
40.

CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.

Kofler DM, Chmielewski M, Rappl G, Hombach A, Riet T, Schmidt A, Hombach AA, Wendtner CM, Abken H.

Mol Ther. 2011 Apr;19(4):760-7. doi: 10.1038/mt.2011.9. Epub 2011 Feb 15.

41.

Eradication of melanomas by targeted elimination of a minor subset of tumor cells.

Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9. doi: 10.1073/pnas.1009069108. Epub 2011 Jan 31.

42.

CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.

Chmielewski M, Hombach AA, Abken H.

Gene Ther. 2011 Jan;18(1):62-72. doi: 10.1038/gt.2010.127. Epub 2010 Oct 14.

PMID:
20944680
43.

[Adoptive T-cell therapy of rhabdomyosarcoma].

Simon-Keller K, Paschen A, Eichmüller S, Gattenlöhner S, Barth S, Koscielniak E, Leuschner I, Stöbel P, Hombach A, Abken H, Marx A.

Pathologe. 2010 Oct;31 Suppl 2:215-20. doi: 10.1007/s00292-010-1344-8. German.

PMID:
20730458
45.

Building better chimeric antigen receptors for adoptive T cell therapy.

Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE.

Curr Gene Ther. 2010 Apr;10(2):77-90. Review.

PMID:
20222863
46.

The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.

Seeger JM, Schmidt P, Brinkmann K, Hombach AA, Coutelle O, Zigrino P, Wagner-Stippich D, Mauch C, Abken H, Krönke M, Kashkar H.

Cancer Res. 2010 Mar 1;70(5):1825-34. doi: 10.1158/0008-5472.CAN-09-3175. Epub 2010 Feb 23.

47.

Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity.

Hombach AA, Kofler D, Rappl G, Abken H.

Gene Ther. 2009 Sep;16(9):1088-96. doi: 10.1038/gt.2009.75. Epub 2009 Jun 25.

PMID:
19554034
48.

Rational development of high-affinity T-cell receptor-like antibodies.

Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E, Kleber S, Nuber N, Stenner-Liewen F, Bauer S, McMichael A, Knuth A, Abken H, Hombach AA, Cerundolo V, Jones EY, Renner C.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5784-8. doi: 10.1073/pnas.0901425106. Epub 2009 Mar 23. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10872. Nuber, Natko [added].

49.

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.

Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kämpgen E, Schuler G, Abken H, Schaft N, Dörrie J.

Gene Ther. 2009 May;16(5):596-604. doi: 10.1038/gt.2008.189. Epub 2009 Jan 22.

PMID:
19158846
50.

Extensive amplification of human regulatory T cells alters their functional capacities and targets them to the periphery.

Rappl G, Schmidt A, Mauch C, Hombach AA, Abken H.

Rejuvenation Res. 2008 Oct;11(5):915-33. doi: 10.1089/rej.2008.0723.

PMID:
18803477

Supplemental Content

Loading ...
Support Center